Johnson & Johnson (JNJ) PT Lowered to $115 at Goldman Sachs, Says Response On Drug Prices Was Underwhelming
Tweet Send to a Friend
Goldman Sachs lowered its price target on Johnson & Johnson (NYSE: JNJ) to $115.00 (from $120.00) while maintaining a Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
